共 16 条
[2]
GLP ‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependence[J] . A. R. Meloni,M. B. DeYoung,C. Lowe,D. G. Parkes.Diabetes Obes Metab . 2012 (1)
[3]
Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?[J] . Gregory Peterson.Annals of Medicine . 2012 (4)
[4]
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
[J].
EUROPEAN HEART JOURNAL,
2012, 33 (12)
:1491-1499
Lonborg, Jacob
;
Vejlstrup, Niels
;
Kelbaek, Henning
;
Botker, Hans Erik
;
Kim, Won Yong
;
Mathiasen, Anders B.
;
Jorgensen, Erik
;
Helqvist, Steffen
;
Saunamaki, Kari
;
Clemmensen, Peter
;
Holmvang, Lene
;
Thuesen, Leif
;
Krusell, Lars Romer
;
Jensen, Jan S.
;
Kober, Lars
;
Treiman, Marek
;
Holst, Jens Juul
;
Engstrom, Thomas
.
[5]
The Synergistic Effect of Valsartan and LAF237[(S)-1-[(3-Hydroxy-1-Adamantyl)Ammo]acetyl-2-Cyanopyrrolidine] on Vascular Oxidative Stress and Inflammation in Type 2 Diabetic Mice[J] . Min Shen,Dongdong Sun,Weijie Li,Bing Liu,Shenxu Wang,Zheng Zhang,Feng Cao,Daisuke Koya.Experimental Diabetes Research . 2012
[6]
Cellular Dysfunction in Diabetes as Maladaptive Response to Mitochondrial Oxidative Stress[J] . Alba Naudi,Mariona Jove,Victoria Ayala,Anna Cassanye,Jose Serrano,Hugo Gonzalo,Jordi Boada,Joan Prat,Manuel Portero-Otin,Reinald Pamplona,Robert A. Harris.Experimental Diabetes Research . 2012
[7]
Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury[J] . Hiromasa Goto,Takashi Nomiyama,Tomoya Mita,Eisuke Yasunari,Kosuke Azuma,Koji Komiya,Masayuki Arakawa,Wen Long Jin,Akio Kanazawa,Ryuzo Kawamori,Yoshio Fujitani,Takahisa Hirose,Hirotaka Watada.Biochemical and Biophysical Research Communications . 2011 (1)
[8]
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase[J] . Shani Ben-Shlomo,Isabel Zvibel,Mati Shnell,Amir Shlomai,Elena Chepurko,Zamir Halpern,Nir Barzilai,Ran Oren,Sigal Fishman.Journal of Hepatology . 2010 (6)
[9]
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)[J] . John B Buse,Julio Rosenstock,Giorgio Sesti,Wolfgang E Schmidt,Eduard Montanya,Jason H Brett,Marcin Zychma,Lawrence Blonde.The Lancet . 2009 (9683)
[10]
Incretin Therapies: Effects Beyond Glycemic Control[J] . Sunder Mudaliar,Robert R. Henry.The American Journal of Medicine . 2009 (6)